BioNxt Solutions Inc.
15.8.2024 22:04:41 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Northfield Announces Change of Corporate Name to Juno International Corporation9.6.2026 21:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 9, 2026 / Northfield Capital Corporation (TSXV:NFD.A) (the "Corporation") today announced that it will change its corporate name to "Juno International Corporation" effective Thursday, June 11, 2026 (the "Name Change"). The trading symbol for the Corporation's class A restricted voting shares (the "Shares") will change to "JUN.A" following the completion of the Name Change. Trading of the Shares on the TSX Venture Exchange under the new name will commence at the open of markets on Thursday, June 11, 2026. There is no change in the capitalization of the Corporation in connection with the Name Change. No action is required by existing shareholders of the Corporation with respect to the Name Change. Outstanding certificates and Direct Registration Statement Advices with respect to the Shares do not need to be exchanged. Upon completion of the Name Change, the Company's new CUSIP number for the Shares will be 482045101 and its new ISIN number will be CA
WLF Energy and Farasis Energy Sign Strategic Partnership Agreement to Accelerate Next-Generation Energy Storage Solutions Globally9.6.2026 15:20:00 CEST | Press release
Partnership combines Farasis Energy's advanced battery technology leadership with WLF Energy's integrated energy platform, AI-driven optimization capabilities, and global deployment strategy STUTTGART, GERMANY / ACCESS Newswire / June 9, 2026 / WLF Energy and Farasis Energy today announced the signing of a Strategic Partnership Agreement to jointly develop, industrialize, and commercialize next-generation battery technologies and energy storage products for global markets. The partnership establishes a long-term framework for collaboration across battery cell technology, battery systems, energy management software, artificial intelligence, and large-scale deployment of energy storage solutions. Together, both companies aim to accelerate the transition toward more affordable, resilient, and sustainable energy infrastructure worldwide. The agreement combines Farasis Energy's extensive experience in advanced battery technology development and manufacturing with WLF Energy's integrated tec
WLF Energy Launches as Europe's Fast, Clean, Bold New Vertically Integrated Clean Energy Champion; Built to Power a Continent9.6.2026 13:30:00 CEST | Press release
Energy platform goes public at The Battery Show Stuttgart, targeting sub-10ct/kWh clean energy for everyone in Europe - and laying the foundation for the continent's energy independence in the decade ahead. STUTTGART, DE / ACCESS Newswire / June 9, 2026 / WLF Energy GmbH today made its public debut at The Battery Show Europe in Stuttgart, unveiling its fully integrated clean-energy platform and long-term mission to deliver affordable, intelligent and sovereign energy infrastructure at global scale. The announcement was delivered by CEO and Chairman Sebastian Wolf, marking the company's first public appearance before a global audience of battery industry leaders, technology innovators and energy investors. The debut signals the arrival of a new kind of European energy company - one designed to integrate generation, storage, intelligence and energy trading into a single platform capable of making clean power the most affordable form of energy in Europe. Founded in 2026, WLF Energy is dev
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom